| A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed' |
Completed |
Budesonide + Formoterol VS. Budesonide + Terbutaline |
3 |
D589SC00003 |
AFH-DH |
| A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients |
Completed |
Travoprost 0.004% / Timolol |
3 |
C-12-008 |
KKESH |
| A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma |
Terminated |
QAW039/Fevipiprant |
3 |
CQAW039A2315 |
KFMC |
| A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma |
Terminated |
QAW039/Fevipiprant |
3 |
CQAW039A2315 |
KFMC |
| A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants |
Completed |
Everolimus + reduced tacrolimus VS.Tacrolimus |
3 |
CRAD001H2307 |
KFSH & RC-R |
| “MERS-CoV Infection Treated with a Combination of Lopinavir/Ritonavir and Interferon Beta 1B: A Placebo-Controlled, Double-Blind Randomized Trial (MIRACLE Trial)” |
Completed |
Kaletra |
3 |
RC15/142/R |
NGHA-R |
| "RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of RAnibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity" |
Completed |
Ranibizumab |
3 |
CRFB002H2301E1 |
KFSH & RC-R |
| Phase 3, Open/Label Study to evaluate the safety and efficacy of TMC 435 plus Pegylated Interferon alfa-2a and Ripavirin administrated for 12 weeks in treatment-naïve Subjects with Chronic genotype 1 or genotype 4 HCV infection |
Completed |
TMC435 (simeprevir) |
3b |
TMC435HPC3014 |
KFSH & RC-R |
| An Open-Label, Multinational, Multicenter, Phase IIIB Study With Subcutaneus Administration Of Trastuzumab In Patient With Her2-Positive Early Breast Cancer To Evaluate Patient Satisfaction |
Terminated |
Trastuzumab SC |
3b |
ML28851 |
KKUH (Closed) |
| An Open-label, Multicentre, Randomised, 2-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Pregnant Women |
Terminated |
Ferrous Sulphate + Ferinject |
3 |
FER-ASAP-2009-01 |
KFSH & RC-R |
